Eksempler på bruk av Objective response rate på Engelsk og deres oversettelse til Norsk
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Objective Response Rate Based on IRR.
Objektiv responsrate basert på IRR.Other endpoints included objective response rate(ORR), OS and safety.
Andre endepunkter inkluderte objektiv responsrate(ORR), OS og sikkerhet.The objective response rate(ORR) based on MRI scans was 8.
Den objektive responsraten(ORR) basert på magnettomografi var 8.Secondary efficacy endpoints were objective response rate(ORR) and overall survival(OS).
Sekundære endepunkter for effekt var objektiv responsrate(ORR) og total overlevelse(OS).Objective response rate= proportion of patients with complete or partial response. .
Objektiv responsrate= andel pasienter med fullstendig eller delvis respons.Secondary endpoints included objective response rate(ORR) and overall survival OS.
Sekundære endepunkter omfattet objektiv responsrate(ORR) og total overlevelse OS.The objective response rate by RECIST in the Tarceva group was 8.9% 95% CI, 6.4 to 12.0.
Objektiv responsrate etter RECIST var i Tarceva-gruppen 8,9 % 95 % KI, 6,4 til 12,0.The primary endpoints of the trial were objective response rate and progression-free survival.
Studiens primære endepunkt var objektiv responsrate og progresjonsfri overlevelse.Objective response rate was low in both treatment arms and the difference was not significant.
Objektiv responsrate var lav i begge behandlingsarmene og forskjellen var ikke signifikant.For subjects with neuroblastoma, the objective response rate was 5.3% 95% CI: 0.1%, 26.0.
For pasienter med nevroblastom var den objektive responsraten 5,3 % 95 % KI: 0,1 %, 26,0.Secondary efficacy endpoints included progression-free survival and objective response rate.
Sekundært endepunkt for effekt inkluderte progresjonsfri overlevelse og objektiv responsrate.COverall objective response rate by IRC.
CSamlet objektiv respons-rate ved IRC.These patients(n=16) showed significant prolongation of PFS(HR of 0.15) and an objective response rate of 31.
Disse pasientene(n=16) viste signifikant forlengelse av PFS(HR på 0,15) og en objektiv responsrate på 31.Objective response rate and duration of response are based on IRF-assessed tumour assessments.
Objektiv responsrate og varighet av respons er basert på IRF-vurdert tumorbedømmelse.The primary efficacy endpoint in both studies was objective response rate(ORR) according to RECIST.
Det primære effektendepunktet i begge studiene var objektiv responsrate(ORR) i henhold til RECIST.The objective response rate for Faslodex 250 mg was 19.2% compared with 16.5% for anastrozole.
Den objektive responsraten for Faslodex 250 mg var 19,2%, sammenlignet med 16,5% for anastrozol.Secondary endpoints included safety, objective response rate, response duration and overall survival OS.
Sekundære endepunkter inkluderte sikkerhet, objektiv responsrate, responsvarighet og total overlevelse OS.The objective response rate(ORR) was 58.0% with trastuzumab plus docetaxel and 64.2% with trastuzumab emtansine.
Objektiv responsrate(ORR) var 58,0 % ved trastuzumab pluss docetaksel og 64,2 % med trastuzumab emtansin.Key secondary efficacy outcome measures were overall survival(OS) and objective response rate(ORR)(see Table 3).
De viktigste sekundære effektendepunktene var totaloverlevelse(OS) og objektiv responsrate(ORR)(se tabell 3).Progression-free survival and objective response rate were inferior in the Avastin monotherapy arm compared to the FOLFOX-4 arm.
Progresjonsfri overlevelse og objektiv responsrate var lavere i armen med Avastin som monoterapi sammenlignet med FOLFOX-4 armen.P-value for PFS/OS based on stratified log-rank test;p-value for Objective Response Rate based on logistic regression.
P-verdi for PFS/OS basert på startifisert log-rank-test,p-verdi for objektiv responsrate basert på logistisk regresjon.In this study the objective response rate was 36.5%(95% CI: 24.7%- 49.6%) and the median time to progression(TTP) was 37.7 weeks 95% CI: 24.0- 46.4 weeks.
I denne studien var den objektive responsraten 36,5 %(95 % KI: 24,7 %- 49,6 %) og median tid til progresjon(TTP) var 37,7 uker 95 % KI: 24,0- 46,4 uker.The combination of cetuximab with irinotecan compared to cetuximab alone reduced the overall risk of disease progression by 46% andsignificantly increased objective response rate.
Cetuximab Palladia-treated dogs had a significantly greater objective response rate(37.2%) compared to dogs treated with placebo 7.9.
Hundene behandlet med Palladia hadde en signifikant høyere objektiv responsrate(37,2 %) sammenlignet med hunder behandlet med placebo 7,9.Objective response rate as assessed by independent review was also similar between eribulin and capecitabine; 11.0%(95% CI: 8.5, 13.9) in the eribulin group and 11.5%(95% CI: 8.9, 14.5) in the capecitabine group.
Objektiv responsgrad ved uavhengig vurdering var også tilsvarende for eribulin og kapecitabin, 11,0 %(95 % KI: 8,5, 13,9) i eribulingruppen og 11,5 %(95 % KI: 8,9, 14,5) i kapecitabingruppen.Secondary efficacy endpoints were overall survival(OS),PFS(investigator-assessed), objective response rate(ORR), duration of response, and time to symptom progression according to the FACT B Quality of Life questionnaire.
De sekundære effektendepunktene var total overlevelse(OS),PFS(vurdert av utprøver), objektiv responsrate(ORR), varighet av respons og tiden til symptomprogresjon i henhold til FACT B“Quality of Life Questionnaire”.The objective response rate(ORR) in those patients who were tumour and ctDNA mutation positive was 77%(95% CI: 66% to 86%) and in those who were tumour only mutation positive 60% 95% CI: 44% to 74.
Den objektive responsraten(ORR) hos de pasientene som var tumor- og ctDNA-mutasjonspositive var 77 %(95 % KI 66 % til 86 %) og hos de som kun var tumor-mutasjonspositive var ORR lik 60 % 95 % KI 44 % til 74.Results from these phase 1 studies and from the NPP experience showed, that in patients with relapsed or refractory HL without prior ASCT,clinically meaningful responses can be achieved as evidenced by an investigator-assessed, objective response rate of 54% and a complete remission rate of 22% after a median of 5 cycles of brentuximab vedotin.
Resultatene fra disse fase 1-studiene og erfaring Deciphera missed the key secondary endpoint of objective response rate, numerically outperforming placebo by 9.4% to zero percent but falling just short statistically.
Deciphera savnet-tasten for sekundære endepunkt av mål svarprosent, numerisk yter bedre enn placebo ved 9.4% til null prosent, men falt bare en kort statistisk.A Plus exemestane b Objective response rate proportion of patients with complete or partial response c Clinical benefit rate proportion of patients with complete or partial response or stable disease.
A Pluss eksemestan b Objektiv responsrate andel pasienter med fullstendig eller delvis respons c Klinisk nytterate andel pasienter med fullstendig eller delvis respons eller stabil sykdom.
